Recent Advances on Paclitaxel-based Self-Delivery Nanomedicine for Cancer Therapy.

Recent Advances on Paclitaxel-based Self-Delivery Nanomedicine for Cancer Therapy.
Curr Med Chem. 2020 Nov 11;:
Authors: Zhou M, Han S, An F
Abstract
Paclitaxel (PTX) is the first natural plant-derived chemotherapeutic drug approved by the Food and Drug Administration. However, the clinical applications of PTX are limited by some drawbacks, such as poor water solubility, rapid blood clearance, nonspecific distribution, and adverse side effects. Nanocarriers have made important contributions for drug delivery and cancer therapy in recent years. However, low drug loading capacity, nanocarrier excipients-induced toxicity or immunogenicity, and complicated synthesis technologies pose a challenge for the clinical application of nanocarriers. To address these issues, the self-delivery nanomedicine (SDNs), in which pure drug molecules directly self-assemble into nanomedicine, have been developed for drug delivery and enhancing antitumor efficacy. In this review, we comprehensively summarize the recent advances on PTX-based SDNs for cancer therapy. First, the self-assembly strategies to develop pure PTX nanodrugs are discussed. Then, the emerging strategies of co-assembly PTX and other therapeutic agents for effective combination therapy are presented, composing of combination chemotherapy, chemo-photothermal therapy, chemophotodynamic therapy, chemo-immunotherapy, and chemo-gene therapy. Finally, the limitations and future outlook of SDNs a...

Source: Current Medicinal Chemistry - November 11, 2020 Category: Chemistry Authors: Zhou M, Han S, An F Tags: Curr Med Chem Source Type: research